Clinical trial Recruiting at 1 site Interventional Ages 18 to 85

Using ethanol infusion to improve atrial fibrillation ablation success

Official title: Randomized Controlled Study of Atrial Posterior Wall Isolation (PWI) Assisted by Vein of Marshall Ethanol Infusion (VOMEI) and Pulmonary Vein Isolation in Persistent Atrial Fibrillation Ablation

Run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · NCT06363604 · Data updated 2026-11-12

This study is testing if adding ethanol infusion to a specific heart procedure can help people with persistent atrial fibrillation have better outcomes and fewer heart rhythm problems after treatment.

More Atrial Fibrillation trials

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment260 (estimated)
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedDecember 1, 2023
Main results expectedSeptember 2026
Study endsNovember 2026
Registry record updatedApril 12, 2024
Trial IDNCT06363604 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-85 with symptomatic, non-valvular persistent atrial fibrillation that has not responded to at least one antiarrhythmic drug.

Probably not a fit

Patients with acute conditions, severe heart failure, or significant comorbidities such as uncontrolled malignancies or liver/kidney dysfunction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of posterior wall isolation (PWI) assisted by vein of Marshall ethanol infusion (VOMEI) in improving the success rate of ablation for persistent atrial fibrillation (AF). A total of 260 participants will be randomly assigned to two groups: one receiving VOMEI along with PWI and linear ablation, and the other receiving VOMEI with linear ablation only. The primary goal is to assess the recurrence of atrial tachyarrhythmias within 3 to 12 months post-procedure, while secondary outcomes will focus on procedural safety and complications.

Why it matters

Potential benefit: If successful, this approach could significantly enhance the effectiveness of atrial fibrillation ablation, leading to better long-term outcomes for patients.

How similar studies have gone: While the specific combination of techniques in this trial may be novel, similar approaches in atrial fibrillation ablation have shown promising results in previous studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Between 18-85 years old;
2. Symptomatic, non-valvular persistent atrial fibrillation (atrial fibrillation duration ≥1 week), and refractory to at least one antiarrhythmic drug;
3. Prepared to undergo atrial fibrillation catheter ablation;
4. Provide informed consent to participate in the study, comply with follow-up trials and evaluation procedures.

Exclusion Criteria:

1. Presence of acute conditions such as acute phase after myocardial infarction (within 3 months), acute heart failure or new onset of cerebral infarction within 3 months;
2. On the heart transplant list;
3. Life expectancy less than 1 year;
4. With other bleeding disorders that cannot be treated with anticoagulation therapy;
5. With left atrial thrombus;
6. Heart failure with NYHA class III-IV or LVEF\<40%;
7. With uncontrolled malignant tumor;
8. Obvious liver or kidney dysfunction (ALT, AST levels more than 2 times the upper limit of normal, and/or CCr\<50%);
9. History of catheter radiofrequency ablation for atrial fibrillation or cardiac surgery;
10. Women who are pregnant, breastfeeding, planning to become pregnant, or of childbearing age but not using reliable contraception.

Where it's running

  • Xinhua Hospital, Shanghai Jiao Tong University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Yigang LI, Dr. — Xinhua Hospital, Shanghai Jiaotong University School of Medicine
  • Study coordinator: Yichi YU, Dr.
  • Email: yuyichi@xinhuamed.com.cn
  • Phone: +8613585563975

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.